Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AbbVie, Advisory, Alcon, alo, avoid, Ballet, Boston, confidence, conserve, CRO, delist, delisted, delisting, difficulty, dire, Distinguished, facilitate, Fine, HLBT, Honorary, ineligible, juncture, microcap, Museum, Orchestra, OTCBB, OTCQB, Overseer, permanent, permanently, pink, quotation, running, shut, shutdown, simultaneously, SPA, sufficent, Symphony, temporarily, timetable, tradability, turn
Removed:
bid, Brigham, exercising, Master, reached, Sabby
Filing tables
Filing exhibits
RGRXD similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements on Form S-8 (Registration Nos. 333-168252, 333-152250, and 333-111386) of RegeneRx Biopharmaceuticals, Inc. (“the Company”) of our report, dated April 11, 2023, on our audits of the financial statements of RegeneRx Biopharmaceuticals, Inc. as of December 31, 2022 and 2021 and for the years then ended, included in this Annual Report on Form 10-K for the year ended December 31, 2022, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern.
/s/ CohnReznick LLP
Tysons, Virginia
April 11, 2023